Cargando…

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53

Background: Sorafenib (Nexavar(®)) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating...

Descripción completa

Detalles Bibliográficos
Autores principales: Omar, Hany A., Tolba, Mai F., Hung, Jui-Hsiang, Al-Tel, Taleb H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127788/
https://www.ncbi.nlm.nih.gov/pubmed/27965580
http://dx.doi.org/10.3389/fphar.2016.00463

Ejemplares similares